Introducing Renasight
A new tool to manage chronic kidney disease.
Renasight is a genetic test for individuals who have been diagnosed with or who have a family history of chronic kidney disease (CKD).
37 million American adults have CKD and 1 in 3 American adults are at risk for kidney disease.1,2
Early detection can help provide management strategies and in some cases slow the progression of CKD.
Built on Evidence3
A recent New England Journal of Medicine publication assessing the incidence of genetic disease in a CKD population found
~1 in 10 patients have a genetic diagnosis.
In 89% of patients of CKD, a genetic diagnosis had implications for clinical management.
"This yield is similar to that observed for cancer, for which genomic diagnostics are routinely used."
Interested in learning more about Renasight
Renasight provides valuable information for disease management.
Benefits of genetic testing
Insight
into progression of CKD
Test
family members for risk of disease
Identify
the underlying cause for CKD of unknown origin
Target
therapies for personalized treatment
Why choose Renasight?
Advanced technology. Seamless integration into your clinical practice.
- Comprehensive: Leverages next generation sequencing and other methodologies on over 380 genes. Test covers both common inherited disorders and less frequent disorders associated with CKD.
- Clinically actionable: Reports out on pathogenic and likely pathogenic variants that were hand selected by genetics experts to provide actionable information.
- Accessible: All insurance plans accepted and affordable testing options available through a variety of payment methods.
- Support: Complimentary information sessions with board-certified genetic counselors.
- Convenience: Remote services during COVID-19. Collection kits can be shipped directly to the patient.
Request more information about Renasight
References
- Chronic Kidney Disease in the United States, 2019. Centers for Disease Control and Prevention.
- Kidney Disease: The Basics. National Kidney Foundation.
- Groopman EE, Marasa M, Cameron-Christie S et al. Diagnostic utility of exome sequencing for kidney disease. NEJM. 2018;doi:10.1056.
The test described has been developed and its performance characteristics determined by the CLIA-certified laboratory performing the test. The test has not been cleared or approved by the US Food and Drug Administration (FDA). Although FDA has generally not enforced the premarket review and other FDA legal requirements for laboratory-developed tests in the US, certification of the laboratory is required under CLIA to ensure the quality and validity of the tests. CAP accredited, ISO 13485, and CLIA certified. © 2020 Natera, Inc. All Rights Reserved.